The Drug Regulatory Authority of Pakistan (DRAP) has announced strict measures against unapproved medicine advertisements. The regulator warned pharmaceutical and nutraceutical companies to seek approval before promoting therapeutic products.
In a notification issued Wednesday, DRAP reminded industry members that the Therapeutic Goods (Advertisement) Rules, 2025, are now in effect. All manufacturers and importers must obtain clearance from the DRAP Advertisement Board before running any advertisement, even if it only announces product availability.
Officials said any unapproved medicine advertisements will be treated as a violation of the law. Companies found in breach may face legal action, and cases involving unlicensed manufacturing units will be referred to the Federal Investigation Agency (FIA) and other law enforcement authorities.
The warning comes after DRAP observed a surge in promotions across television, social media platforms, and roadside billboards. Many advertisements made bold claims about curing conditions such as diabetes, hypertension, infertility, obesity, sexual dysfunction, and mental health disorders.
Authorities also highlighted reports of informal producers selling medicines directly to consumers through social media, call centers, and courier services. Such products may be substandard or unsafe, posing serious risks to public health.
Industry associations have been instructed to inform their members about the rules and ensure strict compliance. DRAP emphasized that applications submitted for advertisement approval under the prescribed procedure will receive priority consideration, but non-compliance will not be tolerated.
Experts say this crackdown is part of broader efforts to regulate medicine marketing and protect consumers from misleading or dangerous claims. DRAP’s move reinforces the legal requirement that all therapeutic product advertisements in Pakistan must first receive official authorization.
By enforcing these regulations, DRAP aims to maintain public safety and prevent the circulation of unverified and potentially harmful medicinal products.
